Tempest Therapeutics, Inc.
$1.94
▼
-1.85%
2026-04-21 09:53:00
www.tempesttx.com
NCM: TPST
Explore Tempest Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$27.83 M
Current Price
$1.94
52W High / Low
$12.23 / $1.5
Stock P/E
—
Book Value
$1.35
Dividend Yield
—
ROCE
-195.16%
ROE
-2.04%
Face Value
—
EPS
$-6.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-1.89
Debt / Equity
122.09
Current Ratio
2.5
Quick Ratio
2.5
Forward P/E
-1.69
Price / Sales
—
Enterprise Value
$29.84 M
EV / EBITDA
-1.13
EV / Revenue
—
Rating
Strong Buy
Target Price
$11
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 2. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 3. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
| 4. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 5. | Sionna Therapeutics, Inc. | $42.64 | — | $1.96 B | — | -28.32% | -31.79% | $46.46 / $9.24 | $6.86 |
| 6. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 7. | NervGen Pharma Corp. | $4 | — | $464.51 M | — | -721.31% | -14.58% | $8.49 / $2.57 | $-0.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.08 M | -3.6 M | -7.97 M | -10.94 M | -13.92 M | — |
| Net Profit | -4.02 M | -3.51 M | -7.87 M | -10.86 M | -13.81 M | — |
| EPS in Rs | -0.28 | -0.24 | -0.55 | -0.76 | -0.96 | -5.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -26.57 M | -42.03 M | -29.16 M | -34.64 M |
| Net Profit | -26.26 M | -41.84 M | -29.49 M | -35.71 M |
| EPS in Rs | -1.83 | -2.92 | -2.06 | -2.49 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 16.93 M | 41.49 M | 51.6 M | 46.09 M |
| Total Liabilities | 10.26 M | 22.36 M | 24.84 M | 27.98 M |
| Equity | 6.67 M | 19.13 M | 26.77 M | 18.11 M |
| Current Assets | 8.27 M | 31.47 M | 40.36 M | 32.95 M |
| Current Liabilities | 3.31 M | 14.22 M | 9.41 M | 7.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -26.82 M | -33.03 M | -27.36 M | -31.07 M |
| Investing CF | 0 M | -0.43 M | -0.17 M | -0.56 M |
| Financing CF | 4.26 M | 24.5 M | 35.6 M | 11.4 M |
| Free CF | -26.82 M | -33.46 M | -27.53 M | -31.63 M |
| Capex | — | -0.43 M | -0.17 M | -0.56 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -41.88% | 17.41% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-09 | 1:0.0769231 |
| 2021-06-28 | 1:0.0666667 |